Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cutting pills, not hope: study probes cancer Patients' views on deprescribing

NCT ID NCT06193083

Knowledge-focused Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how people with advanced cancer feel about stopping or reducing medications that may no longer help. Researchers will interview about 25 patients and survey 300 more to understand their attitudes and beliefs. The goal is to learn what factors influence their views, so doctors can better tailor deprescribing approaches to improve quality of life and reduce side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors design better ways to safely reduce medications for advanced cancer patients, potentially improving quality of life.
What could go wrong
This is an observational study, not a treatment trial. It only gathers opinions, so it won't directly change care. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 325 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

We'll be looking at major patients with "solid" cancer in a palliative situation (locally advanced or metastatic cancer, thus requiring palliative care as defined by the World Health Organization), who have at least one PIMs, followed up on an inpatient or outpatient basis, with a life expectancy estimated at less than 1 year by the doctor caring for the patient. To identify whether a patient has at least one PIMs, we will use the STOPPFrail 2 tool . This is a tool developed in geriatrics, validated for a population with an estimated life expectancy of less than 1 year, and which is not specific to oncology. Life expectancy of less than one year will be estimated by the question surprised by the doctor caring for the patient ("Would you be surprised if your patient died within a year?") . We will carry out a multicenter study in oncology and/or palliative care departments of hospitals located in western France.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient over 18 years of age * Locally advanced or metastatic solid cancer (i.e., palliative care as defined by the World Health Organization) * Life expectancy estimated by the physician at inclusion of less than 1 year (use of surprise question to help clinician estimate life expectancy) * Hospitalized or in consultation * With at least one PIMs (identified using STOPPfrail 2) * Patient not having expressed opposition to participating in the study after receiving information from the physician. For qualitative study patients : \- Patients who have signed an authorization for the recording of their voice during the semi-structured interview for the purpose of written transcription. Exclusion Criteria: * Minor * Major under guardianship, protected person * Patient unable to speak or write French * Patient with impaired judgment, cognitive or sensory impairment that prevents him/her from receiving informed information, answering questionnaires or participating in a study interview.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Deprescribing are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Deprescribing Oncology Palliative care

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH ST Nazaire

    NOT_YET_RECRUITING

    Saint-Nazaire, 44600, France

  • CHD Vendée

    NOT_YET_RECRUITING

    La Roche-sur-Yon, 85000, France

  • CHRU Tours

    NOT_YET_RECRUITING

    Tours, France

  • CHU de Nantes

    RECRUITING

    Nantes, 44093, France

  • Hospices Civils de Lyon

    NOT_YET_RECRUITING

    Lyon, France

  • Hôpital Institut CURIE

    NOT_YET_RECRUITING

    Paris, 75005, France

  • Institut de Cancérologie de l'Ouest

    NOT_YET_RECRUITING

    Saint-Herblain, 44800, France

  • USP - Maison de Nicodème

    NOT_YET_RECRUITING

    Nantes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.